Minnesota Oncology

Pancreatic Cancer News

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival (July 10, 2014)

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (gemcitabine).... Continue Reading

Aspirin Reduces Risk of Pancreatic Cancer (July 1, 2014)

The results of a recent study suggest that regular aspirin use reduces the risk of pancreatic cancer by half.  Clinical studies have also found that regular aspirin use can reduce the risk for colon, esophageal, lung and prostate cancers, as well as... Continue Reading

Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy (July 1, 2014)

A follow up report on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study of Abraxane® (nab-paclitaxel) in combination with Gemzar® (gemcitabine) in previously untreated patients with metastatic pancreatic cancer... Continue Reading

Ruxolitinib Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation (June 2, 2014)

In a study presented at the 2014 ASCO meeting and published in the Journal of Clinical Oncology, researchers reported that treatment with ruxolitinib plus capecitabine improved overall survival and progression-free survival in metastatic pancreatic cancer... Continue Reading

Radioimmunotherapy and Gemcitabine Combination Shows Extended Survival Times for Metastatic Pancreatic Ductal Cancer Patients (May 23, 2014)

In a recent study presented at the American Association for Cancer Research conference on Pancreatic Cancer: Innovation in Research and Treatment, researchers reported that a combination therapy of gemcitabine and radioimmunotherapy (fractionated doses... Continue Reading

Dual Vaccines Prolong Survival in Metastatic Pancreatic Cancer (February 5, 2014)

The sequential delivery of two vaccines—GVAX and CRS-207—prolonged survival in patients with metastatic pancreatic cancer by about two months, according to the results of a study presented at the 2014 Gastorintestinal Cancers Symposium in San Francisco,... Continue Reading

Abraxane Plus Gemzar Improves Survival in Metastatic Pancreatic Cancer (December 25, 2013)

Abraxane® (nab-paclitaxel) plus Gemzar® (gemcitabine) improved overall and progression-free survival in patients with previously untreated metastatic pancreatic cancer, according to the results of a study published in the New England Journal of Medicine. Pancreatic... Continue Reading

Abraxane Approved for Metastatic Pancreatic Cancer (September 20, 2013)

The U.S. Food and Drug Administration (FDA) has approved Abraxane® (paclitaxel protein-bound particles for injectable suspension, albumin-bound) for the treatment of patients with metastatic pancreatic cancer. Pancreatic cancer is one of the deadliest... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Latest Pancreatic Cancer News By Stage


Recurrent Pancreatic Cancer

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival (July 10, 2014)

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (gemcitabine).... Continue Reading

Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy (July 1, 2014)

A follow up report on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study of Abraxane® (nab-paclitaxel) in combination with Gemzar® (gemcitabine) in previously untreated patients with metastatic pancreatic cancer... Continue Reading

Dual Vaccines Prolong Survival in Metastatic Pancreatic Cancer (February 5, 2014)

The sequential delivery of two vaccines—GVAX and CRS-207—prolonged survival in patients with metastatic pancreatic cancer by about two months, according to the results of a study presented at the 2014 Gastorintestinal Cancers Symposium in San Francisco,... Continue Reading

Abraxane Plus Gemzar Improves Survival in Metastatic Pancreatic Cancer (December 25, 2013)

Abraxane® (nab-paclitaxel) plus Gemzar® (gemcitabine) improved overall and progression-free survival in patients with previously untreated metastatic pancreatic cancer, according to the results of a study published in the New England Journal of Medicine. Pancreatic... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

More Recurrent Pancreatic Cancer

Screening/Prevention Pancreatic Cancer

Aspirin Reduces Risk of Pancreatic Cancer (July 1, 2014)

The results of a recent study suggest that regular aspirin use reduces the risk of pancreatic cancer by half.  Clinical studies have also found that regular aspirin use can reduce the risk for colon, esophageal, lung and prostate cancers, as well as... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Lynch Syndrome Also Linked with Breast and Pancreatic Cancer (February 17, 2012)

A study of families with Lynch Syndrome has expanded the list of cancers related to the condition: carriers of a Lynch Syndrome gene mutation also appear to have an increased risk of breast cancer and pancreatic cancer. These results were published in... Continue Reading

Test Holds Promise for Early Detection of Pancreatic Cancer (January 24, 2012)

A test that detects a particular protein in the blood (PAM4) correctly identified roughly two-thirds of patients with early-stage pancreatic cancer. These results were presented at the 2012 Gastrointestinal Cancers Symposium. Pancreatic cancer is one... Continue Reading

Processed Meat Linked with Increased Risk of Pancreatic Cancer (January 18, 2012)

Eating processed meat such as sausage or bacon appears to increase the risk of pancreatic cancer. These results were published in the British Journal of Cancer. Pancreatic cancer is one of the deadliest forms of cancer. Each year, close to 44,000 people... Continue Reading

More Screening/Prevention Pancreatic Cancer

Stage IV Pancreatic Cancer

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival (July 10, 2014)

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (gemcitabine).... Continue Reading

Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy (July 1, 2014)

A follow up report on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study of Abraxane® (nab-paclitaxel) in combination with Gemzar® (gemcitabine) in previously untreated patients with metastatic pancreatic cancer... Continue Reading

Ruxolitinib Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation (June 2, 2014)

In a study presented at the 2014 ASCO meeting and published in the Journal of Clinical Oncology, researchers reported that treatment with ruxolitinib plus capecitabine improved overall survival and progression-free survival in metastatic pancreatic cancer... Continue Reading

Radioimmunotherapy and Gemcitabine Combination Shows Extended Survival Times for Metastatic Pancreatic Ductal Cancer Patients (May 23, 2014)

In a recent study presented at the American Association for Cancer Research conference on Pancreatic Cancer: Innovation in Research and Treatment, researchers reported that a combination therapy of gemcitabine and radioimmunotherapy (fractionated doses... Continue Reading

Dual Vaccines Prolong Survival in Metastatic Pancreatic Cancer (February 5, 2014)

The sequential delivery of two vaccines—GVAX and CRS-207—prolonged survival in patients with metastatic pancreatic cancer by about two months, according to the results of a study presented at the 2014 Gastorintestinal Cancers Symposium in San Francisco,... Continue Reading

More Stage IV Pancreatic Cancer

Stages I-III Pancreatic Cancer

Ruxolitinib Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation (June 2, 2014)

In a study presented at the 2014 ASCO meeting and published in the Journal of Clinical Oncology, researchers reported that treatment with ruxolitinib plus capecitabine improved overall survival and progression-free survival in metastatic pancreatic cancer... Continue Reading

Radioimmunotherapy and Gemcitabine Combination Shows Extended Survival Times for Metastatic Pancreatic Ductal Cancer Patients (May 23, 2014)

In a recent study presented at the American Association for Cancer Research conference on Pancreatic Cancer: Innovation in Research and Treatment, researchers reported that a combination therapy of gemcitabine and radioimmunotherapy (fractionated doses... Continue Reading

Sutent Approved for Pancreatic Neuroendocrine Tumors (PNET) (June 2, 2011)

The US Food and Drug Administration has approved the targeted drug Sutent® (sunitinib) for the treatment pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are an uncommon type of cancer that develops in the hormone-producing cells... Continue Reading

New Approach to Immune Therapy Shows Promise against Pancreatic Cancer (April 1, 2011)

An investigational type of immune therapy that attacks the tissue around a tumor has shown promise in a small study of patients with advanced pancreatic cancer. These results were published in the journal Science. Immune therapies stimulate the body’s... Continue Reading

Addition of Axitinib Fails to Improve Pancreatic Cancer Outcomes (February 23, 2011)

Among patients with advanced pancreatic cancer, treatment with a combination of Gemzar® (gemcitabine) and the investigational drug axitinib did not result in better outcomes than treatment with Gemzar alone. The results of this Phase III clinical trial... Continue Reading

More Stages I-III Pancreatic Cancer